The “Irritable Bowel Syndrome – Pipeline Insight, 2021” drug pipelines have been added to ResearchAndMarkets.com’s offering.
This Irritable bowel syndrome – Pipeline Insight, 2021 report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in the Irritable bowel syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Irritable bowel syndrome Emerging Drugs Chapters
This segment of the Irritable bowel syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Irritable bowel syndrome Emerging Drugs
Olorinab: Arena Pharmaceuticals
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Olorinab (APD371) is an oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain in gastrointestinal disorders. This compound, through its selectivity for CB2, versus the cannabinoid receptor 1 (CB1), was designed to provide pain relief while minimizing the risk of psychoactive adverse effects. The drug is currently in phase 2 of clinical trials for the treatment of irritable bowel syndrome.
Blautix: 4D Pharma
Blautix is a single-strain Live Biotherapeutic Product (LBP), being developed as a treatment for both IBS-C and IBS-D. Pre-clinical studies demonstrated its ability to address visceral hypersensitivity and other symptoms of IBS and increase microbiome diversity. A Phase I study in healthy volunteers and IBS patients showed that Blautix was well tolerated and an improvement in symptoms was also reported relative to placebo. The Phase II BHT-II-002 trial demonstrated an impact on overall response with regards to bowel habit and abdominal pain in IBS-C and IBS-D. Blautix was well tolerated, with a safety profile comparable to placebo.
Irritable bowel syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Irritable bowel syndrome drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Irritable bowel syndrome
There are approx. 24+ key companies are developing therapies for Irritable bowel syndrome. The companies which have their Irritable bowel syndrome drug candidates in the most advanced stage, i.e. phase II include Arena Pharmaceuticals.
Source: Businesswire
